| Gothenburg (N=424) |
Northern (N=493) |
Stockholm CFN Karolinska (N=1441) |
Stockholm Danderyd (N=328) |
Overall (N=2686) |
|
|---|---|---|---|---|---|
| Sex | |||||
| Kvinna | 282 (66.5%) | 330 (66.9%) | 993 (68.9%) | 232 (70.7%) | 1837 (68.4%) |
| Man | 142 (33.5%) | 162 (32.9%) | 447 (31.0%) | 96 (29.3%) | 847 (31.5%) |
| Missing | 0 (0%) | 1 (0.2%) | 1 (0.1%) | 0 (0%) | 2 (0.1%) |
| Age | |||||
| Mean (SD) | 43.5 (12.3) | 40.7 (11.6) | 41.9 (11.6) | 41.7 (10.8) | 41.9 (11.6) |
| Median [Min, Max] | 43.0 [9.70, 74.6] | 40.8 [13.5, 75.1] | 41.8 [14.4, 77.1] | 41.7 [15.7, 69.6] | 41.9 [9.70, 77.1] |
| Missing | 0 (0%) | 1 (0.2%) | 2 (0.1%) | 0 (0%) | 3 (0.1%) |
| BMI | |||||
| Mean (SD) | 25.6 (4.94) | 27.4 (6.94) | 25.3 (5.11) | 25.8 (5.47) | 25.7 (5.46) |
| Median [Min, Max] | 24.7 [17.5, 46.6] | 25.2 [16.3, 49.8] | 24.3 [14.5, 61.6] | 25.2 [13.7, 49.9] | 24.6 [13.7, 61.6] |
| Missing | 252 (59.4%) | 288 (58.4%) | 477 (33.1%) | 111 (33.8%) | 1128 (42.0%) |
| MS type | |||||
| NA | 1 (0.2%) | 0 (0%) | 2 (0.1%) | 1 (0.3%) | 4 (0.1%) |
| PPMS | 38 (9.0%) | 28 (5.7%) | 72 (5.0%) | 6 (1.8%) | 144 (5.4%) |
| RRMS | 278 (65.6%) | 381 (77.3%) | 1006 (69.8%) | 266 (81.1%) | 1931 (71.9%) |
| SPMS | 107 (25.2%) | 84 (17.0%) | 361 (25.1%) | 55 (16.8%) | 607 (22.6%) |
| EDSS | |||||
| Mean (SD) | 3.09 (2.14) | 2.17 (1.89) | 2.82 (1.94) | 2.10 (1.74) | 2.68 (1.98) |
| Median [Min, Max] | 2.50 [0, 8.75] | 2.00 [0, 8.00] | 2.50 [0, 8.75] | 1.75 [0, 9.00] | 2.00 [0, 9.00] |
| Missing | 55 (13.0%) | 186 (37.7%) | 279 (19.4%) | 38 (11.6%) | 558 (20.8%) |
| Previous treatment | |||||
| Cladribine | 23 (5.4%) | 1 (0.2%) | 16 (1.1%) | 2 (0.6%) | 42 (1.6%) |
| Fumarate | 36 (8.5%) | 20 (4.1%) | 125 (8.7%) | 44 (13.4%) | 225 (8.4%) |
| Glatiramer_acetate | 12 (2.8%) | 20 (4.1%) | 61 (4.2%) | 13 (4.0%) | 106 (3.9%) |
| Interferon | 41 (9.7%) | 118 (23.9%) | 297 (20.6%) | 60 (18.3%) | 516 (19.2%) |
| Natalizumab | 118 (27.8%) | 104 (21.1%) | 242 (16.8%) | 76 (23.2%) | 540 (20.1%) |
| Other | 24 (5.7%) | 32 (6.5%) | 54 (3.7%) | 10 (3.0%) | 120 (4.5%) |
| Other Anti-CD20 | 8 (1.9%) | 1 (0.2%) | 30 (2.1%) | 10 (3.0%) | 49 (1.8%) |
| S1PR-inhibitors | 30 (7.1%) | 21 (4.3%) | 147 (10.2%) | 15 (4.6%) | 213 (7.9%) |
| Teriflunomide | 15 (3.5%) | 1 (0.2%) | 22 (1.5%) | 5 (1.5%) | 43 (1.6%) |
| Missing | 117 (27.6%) | 175 (35.5%) | 447 (31.0%) | 93 (28.4%) | 832 (31.0%) |
| IgG | |||||
| Mean (SD) | 9.59 (2.23) | 9.56 (2.17) | 10.0 (2.18) | 9.78 (2.06) | 9.84 (2.18) |
| Median [Min, Max] | 9.40 [2.30, 17.0] | 9.41 [4.26, 19.0] | 9.84 [4.37, 20.6] | 9.69 [4.98, 16.3] | 9.67 [2.30, 20.6] |
| Missing | 5 (1.2%) | 5 (1.0%) | 9 (0.6%) | 0 (0%) | 19 (0.7%) |
| Neutrophils | |||||
| Mean (SD) | 4.17 (1.27) | 4.01 (1.15) | 4.09 (1.36) | 3.84 (1.17) | 4.06 (1.29) |
| Median [Min, Max] | 3.95 [1.12, 11.4] | 3.90 [1.83, 9.38] | 3.87 [1.22, 15.2] | 3.72 [1.03, 10.0] | 3.87 [1.03, 15.2] |